Crohn’s disease in Korea: Past, present, and future

Korean Journal of Internal Medicine

Volumn 29, Issue 5, 2014, Pages 558-570

  Lee, Kang Moon ^a   Lee, Ji Min ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Crohn disease; Epidemiology; Genetics; Korea; Prognosis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BACTERIUM ANTIBODY; BIOLOGICAL PRODUCT; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 23 RECEPTOR; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; NEUTROPHIL CYTOPLASMIC ANTIBODY; SACCHAROMYCES CEREVISIAE ANTIBODY; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ADIPOSE DERIVED STEM CELL; AGE DISTRIBUTION; ANTIBODY DETECTION; ANUS FISTULA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BEHCET DISEASE; BONE MARROW TOXICITY; CLINICAL FEATURE; COHORT ANALYSIS; COLONOSCOPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ETHNIC GROUP; FAMILY HISTORY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; GEOGRAPHIC DISTRIBUTION; HERPES ZOSTER; HUMAN; IMMUNE DYSREGULATION; INFUSION RELATED REACTION; INTERFERON GAMMA RELEASE ASSAY; INTESTINE ENDOSCOPY; INTESTINE EXAMINATION; INTESTINE RESECTION; INTESTINE TUBERCULOSIS; KOREA; LIVER ABSCESS; LUNG TUBERCULOSIS; MOLECULAR GENETICS; MORBIDITY; MULTICENTER STUDY (TOPIC); ONSET AGE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PROGNOSIS; REMISSION; REVIEW; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SEX DIFFERENCE; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; SURGICAL DRAINAGE; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; FEMALE; MALE; SOUTH KOREA;

CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; PROGNOSIS; REPUBLIC OF KOREA;

EID: 84907150178     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2014.29.5.558     Document Type: Review

References (87)

1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis 2002;8:244-250.
2. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;5:1430-1438.
3. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008;14:542-549.
4. Ng SC, Tsoi KK, Kamm MA, et al. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm Bowel Dis 2012;18:1164-1176.
5. Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver 2010;4:1-14.
6. Kim KY, Suh SH, Chang MW, Min KS. Crohn’s disease: case report and article review. J Korean Surg Soc 1964;6:121-131.
7. Ye BD, Jang BI, Jeen YT, et al. Diagnostic guideline of Crohn’s disease. Korean J Gastroenterol 2009;53:161-176.
8. Ye BD, Yang SK, Shin SJ, et al. Guidelines for the management of Crohn’s disease. Intest Res 2012;10:26-66.
9. Lee CK, Kim HS, Ye BD, et al. Patients with Crohn’s disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis 2014;8:384-391.
10. Moon CM, Park DI, Kim ER, et al. Clinical features and predictors of clinical outcomes in Korean patients with Crohn’s disease: a Korean association for the study of intestinal diseases multicenter study. J Gastroenterol Hepatol 2014;29:74-82.
11. Bae JH, Park J, Yang KM, Kim TO, Yi JM; IBD Study Group of Korean Association for Study of Intestinal Diseases (KASID). Detection of DNA hypermethylation in sera of patients with Crohn’s disease. Mol Med Rep 2014;9:725-729.
12. Cheon JH, Kim YS, Ye BD, et al. Crohn’s Disease Clinical Network and Cohort (CONNECT) study: the first step toward nationwide multicenter research of Crohn’s disease in Korea. Intest Res 2014;12:173-175.
13. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inf lammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.
14. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci 2013;58:519-525.
15. Lakatos L, Kiss LS, David G, et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis 2011;17:2558-2565.
16. Lowe AM, Roy PO, M BP, et al. Epidemiology of Crohn’s disease in Quebec, Canada. Inf lamm Bowel Dis 2009;15:429-435.
17. Burisch J, Pedersen N, Cukovic-Cavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2014;63:588-597.
18. Shin DH, Sinn DH, Kim YH, et al. Increasing incidence of inf lammatory bowel disease among young men in Korea between 2003 and 2008. Dig Dis Sci 2011;56:1154-1159.
19. Ye BD, Han DS, Youn EJ, et al. The clinical features and prognosis of Crohn’s disease: a Korean multicenter nationwide cohort study. 9th Congress of European Crohn’s and Colitis Organization; 2014 Feb 20-22; Copenhagen. Vienna: ECCO, 2014: 591.
20. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006;101:1274-1282.
21. Oriuchi T, Hiwatashi N, Kinouchi Y, et al. Clinical course and longterm prognosis of Japanese patients with Crohn’s disease: predictive factors, rates of operation, and mortality. J Gastroenterol 2003;38:942-953.
22. Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J Gastroenterol 2009;44:659-665.
23. Chuang CH, Lin SH, Chen CY, Sheu BS, Kao AW, Wang JD. Increasing incidence and lifetime risk of inf lammatory bowel disease in Taiwan: a nationwide study in a low-endemic area 1998-2010. Inf lamm Bowel Dis 2013;19:2815-2819.
24. Zeng Z, Zhu Z, Yang Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol 2013;28:1148-1153.
25. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006;101:1559-1568.
26. Gearry RB, Richardson A, Frampton CM, et al. High incidence of Crohn’s disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis 2006;12:936-943.
27. Park SH, Yang SK, Park SK, et al. Long-term prognosis of Crohn’s disease and its temporal change between 1981 and 2012: a hospital-based cohort study from Korea. Inflamm Bowel Dis 2014;20:488-494.
28. Park JB, Yang SK, Byeon JS, et al. Familial occurrence of inflammatory bowel disease in Korea. Inflamm Bowel Dis 2006;12:1146-1151.
29. Podolsky DK. Inf lammatory bowel disease. N Engl J Med 2002;347:417-429.
30. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307-317.
31. Liu JZ, Anderson CA. Genetic studies of Crohn’s disease: past, present and future. Best Pract Res Clin Gastroenterol 2014;28:373-386.
32. Croucher PJ, Mascheretti S, Hampe J, et al. Haplotype structure and association to Crohn’s disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet 2003;11:6-16.
33. Lee GH, Kim CG, Kim JS, Jung HC, Song IS. Frequency analysis of NOD2 gene mutations in Korean patients with Crohn’s disease. Korean J Gastroenterol 2005;45:162-168.
34. Yang SK, Park M, Lim J, et al. Contribution of IL23R but not ATG16L1 to Crohn’s disease susceptibility in Koreans. Inflamm Bowel Dis 2009;15:1385-1390.
35. Jang JY, Song SM, Kim KM, Oh SH, Lee YJ, Rhee KW. Lack of common NOD2 mutations in Korean pediatric patients with inflammatory bowel disease. Pediatr Int 2010;52:888-889.
36. Yang SK, Lim J, Chang HS, et al. Association of TNFSF15 with Crohn’s disease in Koreans. Am J Gastroenterol 2008;103:1437-1442.
37. Kim SW, Kim ES, Moon CM, et al. Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inf lammatory bowel disease. Gut 2011;60:1527-1536.
38. Moon CM, Shin DJ, Kim SW, et al. Associations between genetic variants in the IRGM gene and inf lammatory bowel diseases in the Korean population. Inf lamm Bowel Dis 2013;19:106-114.
39. Yang SK, Hong M, Zhao W, et al. Genome-wide association study of Crohn’s disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations. Gut 2014;63:80-87.
40. Kim TH, Kim BG, Shin HD, et al. Tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in Korean patients with inflammatory bowel disease. Korean J Gastroenterol 2003;42:377-386.
41. Yang SK, Lee SG, Cho YK, Lim J, Lee I, Song K. Association of TNF-alpha/LTA polymorphisms with Crohn’s disease in Koreans. Cytokine 2006;35:13-20.
42. Li CS, Zhang Q, Lee KJ, et al. Interleukin-27 polymorphisms are associated with inf lammatory bowel diseases in a Korean population. J Gastroenterol Hepatol 2009;24:1692-1696.
43. Yang DH, Yang SK, Song K, et al. TNFSF15 is an independent predictor for the development of Crohn’s disease-related complications in Koreans. J Crohns Colitis 2014 May 13 [Epub]. http://dx.doi.org/10.1016/ j.crohns.2014.04.002.
44. Ye BD, Yang SK, Cho YK, et al. Clinical features and long-term prognosis of Crohn’s disease in Korea. Scand J Gastroenterol 2010;45:1178-1185.
45. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classif ication of inf lammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-753.
46. American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: perianal Crohn’s disease. Gastroenterology 2003;125:1503-1507.
47. Canani RB, Romano MT, Greco L, et al. Effects of disease activity on anti-Saccharomyces cerevisiae antibodies: implications for diagnosis and follow-up of children with Crohn’s disease. Inflamm Bowel Dis 2004;10:234-239.
48. Nikolaus S, Schreiber S. Diagnostics of inf lammatory bowel disease. Gastroenterology 2007;133:1670-1689.
49. Kim BG, Kim YS, Kim JS, Jung HC, Song IS. Diagnostic role of anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inf lammatory bowel disease. Dis Colon Rectum 2002;45:1062-1069.
50. Kim BC, Park S, Han J, Kim JH, Kim TI, Kim WH. Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn’s disease and its relationship to the disease clinical course. Dig Liver Dis 2007;39:610-616.
51. Park JB, Yang SK, Myung SJ, et al. Clinical characteristics at diagnosis and course of Korean patients with Crohn’s disease. Korean J Gastroenterol 2004;43:8-17.
52. Lee YJ, Yang SK, Byeon JS, et al. Analysis of colonoscopic findings in the differential diagnosis between intestinal tuberculosis and Crohn’s disease. Endoscopy 2006;38:592-597.
53. Kim YS, Kim YH, Kim WH, et al. Diagnostic utility of anti-Saccharomyces cerevisiae antibody (ASCA) and interferon-gamma assay in the differential diagnosis of Crohn’s disease and intestinal tuberculosis. Clin Chim Acta 2011;412:1527-1532.
54. Kim BJ, Choi YS, Jang BI, et al. Prospective evaluation of the clinical utility of interferon-gamma assay in the differential diagnosis of intestinal tuberculosis and Crohn’s disease. Inflamm Bowel Dis 2011;17:1308-1313.
55. Lee SK, Kim BK, Kim TI, Kim WH. Differential diagnosis of intestinal Behcet’s disease and Crohn’s disease by colonoscopic findings. Endoscopy 2009;41:9-16.
56. Lee SS, Kim AY, Yang SK, et al. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology 2009;251:751-761.
57. Jung YS, Park DI, Kim ER, et al. Quantifying exposure to diagnostic radiation and factors associated with exposure to high levels of radiation in Korean patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1852-1857.
58. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inf lammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-260.
59. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 2005;54:237-241.
60. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inf lammatory bowel disease. Aliment Pharmacol Ther 2008;28:674-688.
61. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010;4:28-62.
62. Antunes O, Filippi J, Hebuterne X, Peyrin-Biroulet L. Treatment algorithms in Crohn’s: up, down or something else? Best Pract Res Clin Gastroenterol 2014;28:473-483.
63. Kim DH, Cheon JH, Park JJ, et al. Clinical outcomes and predictive factors for response after the first course of corticosteroid therapy in patients with Crohn’s disease. Gut Liver 2013;7:58-65.
64. Kwak MS, Kim DH, Park SJ, et al. Efficacy of early immunomodulator therapy on the outcomes of Crohn’s disease. BMC Gastroenterol 2014;14:85.
65. Kim JH, Cheon JH, Kim WH. The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease. Korean J Gastroenterol 2008;51:291-297.
66. Kim JH, Cheon JH, Hong SS, et al. Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inf lammatory bowel disease: a retrospective cohort study. J Clin Gastroenterol 2010;44:e242-e248.
67. Kim SH, Yang S, Kim KJ, et al. Efficacy of infliximab in the treatment of Korean patients with Crohns disease. Korean J Gastroenterol 2009;54:108-116.
68. Kim YJ, Kim JW, Lee CK, et al. Clinical outcome of treatment with infliximab in Crohn’s disease: a single-center experience. Korean J Gastroenterol 2013;61:270-278.
69. Choi CH, Song ID, Cha BK, Chang SK, Kim YH, Kim WH. The efficacy and safety of inf liximab therapy in Korean patients with Crohn’s diseases: a retrospective, multicenter study. Gastroenterology 2012;142(5 Suppl 1):S353.
70. Jo KW, Hong Y, Jung YJ, et al. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis. Respir Med 2013;107:1797-1802.
71. Byun JM, Lee CK, Rhee SY, et al. Risk of tuberculosis in inf lammatory bowel disease patients treated with tumor necrosis factor-a blockers: a multicenter study in Korea. Oral presented at: The 2nd Annual Meeting of Asian Organization for Crohn’s & Colitis; 2014 Jun 19-21; Seoul, Korea.
72. McLeod RS. Surgery for inflammatory bowel diseases. Dig Dis 2003;21:168-179.
73. Thirlby RC, Land JC, Fenster LF, Lonborg R. Effect of surgery on health-related quality of life in patients with inflammatory bowel disease: a prospective study. Arch Surg 1998;133:826-832.
74. Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol 2009;104:465-483.
75. Garcia JC, Persky SE, Bonis PA, Topazian M. Abscesses in Crohn’s disease: outcome of medical versus surgical treatment. J Clin Gastroenterol 2001;32:409-412.
76. Gervais DA, Hahn PF, O’Neill MJ, Mueller PR. Percutaneous abscess drainage in Crohn disease: technical success and short-and long-term outcomes during 14 years. Radiology 2002;222:645-651.
77. Kim DH, Cheon JH, Moon CM, et al. Clinical efficacy of nonsurgical treatment of Crohn’s disease-related intraabdominal abscess. Korean J Gastroenterol 2009;53:29-35.
78. Lee H, Kim YH, Kim JH, et al. Nonsurgical treatment of abdominal or pelvic abscess in consecutive patients with Crohn’s disease. Dig Liver Dis 2006;38:659-664.
79. Kim HD, Kim CG, Kim JW, et al. Clinical features and therapeutic responses of perianal lesions in Crohn’s disease. Korean J Gastroenterol 2003;42:128-133.
80. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398-1405.
81. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876-885.
82. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 2005;128:862-869.
83. Lee WY, Park KJ, Cho YB, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn’s fistula. Stem Cells 2013;31:2575-2581.
84. Lee KY, Yu CS, Lee KY, et al. Risk factors for repeat abdominal surgery in Korean patients with Crohn’s disease: a multi-center study of a Korean inflammatory bowel disease study group. J Korean Soc Coloproctol 2012;28:188-194.
85. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990;99:956-963.
86. De Cruz P, Kamm MA, Prideaux L, Allen PB, Desmond PV. Postoperative recurrent luminal Crohn’s disease: a systematic review. Inflamm Bowel Dis 2012;18:758-777.
87. Lee YW, Lee KM, Chung WC, Paik CN, Sung HJ, Oh YS. Clinical and endoscopic recurrence after surgical resection in patients with Crohn’s disease. Intest Res 2014;12:117-123.